Relationship between apoE genotype and CSF β-amyloid (1-42) and tan in patients with probable and definite Alzheimer's disease

被引:90
作者
Tapiola, T
Pirttilä, T
Mehta, PD
Alafuzoff, I
Lehtovirta, M
Soininen, H
机构
[1] Kuopio Univ Hosp, Dept Neurol & Neurosci, FIN-70211 Kuopio, Finland
[2] Univ Kuopio, FIN-70211 Kuopio, Finland
[3] Inst Basic Res Dev Disabilities, Staten Isl, NY USA
[4] Kuopio Univ Hosp, Dept Pathol, FIN-70211 Kuopio, Finland
基金
芬兰科学院; 英国医学研究理事会;
关键词
Alzheimer's disease; dementia; cerebrospinal fluid; CSF; tau; beta-amyloid; apolipoprotein E;
D O I
10.1016/S0197-4580(00)00164-0
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
We investigated the usefulness of cerebrospinal fluid (CSF) beta-amyloid42 (A beta 42), beta-amyloid40 (A beta 40) and tau analyses in the diagnosis of Alzheimer's disease (AD). The study included 41 definite AD cases, 80 patients with probable AD, 27 with other dementias and 39 neurological controls. A beta 42, A beta 40 and tau protein concentrations in CSF were measured of using ELISA assays. A beta 42 levels were decreased and tan increased in AD. Combination of A beta 42 and tau resulted a sensitivity of 50.4% for AD and specificities of 94.8% for controls and 85.2% for other dementias. Ninety-one percent of the patients with A beta 42 below the cutoff value (340 pg/ml) and tau above the cutoff value (380 pg/ml) had AD. AD patients carrying apoE epsilon 4 allele had lower A beta 42 (P < 0.005) and higher tau (P < 0.05) levels than those without an epsilon 4 allele, and 18 (81.8%) of the 22 AD patients who had normal A beta 42 and tau levels were apoE epsilon 4 allele non-carriers. Low A beta 42 and high tau concentration in CSF strongly support the diagnosis of AD. Measurement of A beta 42 may help the early diagnosis of cases at risk for AD such as apoE epsilon 4 allele carriers. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:735 / 740
页数:6
相关论文
共 31 条
[1]  
Alzheimers Assoc, 1998, NEUROBIOL AGING, V19, P109
[2]   TAU IN CEREBROSPINAL-FLUID - A POTENTIAL DIAGNOSTIC MARKER IN ALZHEIMERS-DISEASE [J].
ARAI, H ;
TERAJIMA, M ;
MIURA, L ;
HIGUCHI, S ;
MURAMATSU, T ;
MACHIDA, N ;
SEIKI, H ;
TAKASE, S ;
CLARK, CM ;
LEE, VMY ;
TROJANOWSKI, JQ ;
SASAKI, H .
ANNALS OF NEUROLOGY, 1995, 38 (04) :649-652
[3]   Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up [J].
Blomberg, M ;
Jensen, M ;
Basun, H ;
Lannfelt, L ;
Wahlund, LO .
NEUROSCIENCE LETTERS, 1996, 214 (2-3) :163-166
[4]   The cholinergic hypothesis of Alzheimer's disease: a review of progress [J].
Francis, PT ;
Palmer, AM ;
Snape, M ;
Wilcock, GK .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 66 (02) :137-147
[5]   Assessment of CSF levels of tan protein in mildly demented patients with Alzheimer's disease [J].
Galasko, D ;
Clark, C ;
Chang, L ;
Miller, B ;
Green, RC ;
Motter, R ;
Seubert, P .
NEUROLOGY, 1997, 48 (03) :632-635
[6]   High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype [J].
Galasko, D ;
Chang, L ;
Motter, R ;
Clark, CM ;
Kaye, J ;
Knopman, D ;
Thomas, R ;
Kholodenko, D ;
Schenk, D ;
Lieberburg, I ;
Miller, B ;
Green, R ;
Basherad, R ;
Kertiles, L ;
Boss, MA ;
Seubert, P .
ARCHIVES OF NEUROLOGY, 1998, 55 (07) :937-945
[7]   Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease [J].
Golombowski, S ;
MullerSpahn, F ;
Romig, H ;
Mendla, K ;
Hock, C .
NEUROSCIENCE LETTERS, 1997, 225 (03) :213-215
[8]   ALZHEIMER PATHOLOGY OF PATIENTS CARRYING APOLIPOPROTEIN-E EPSILON-4 ALLELE [J].
HEINONEN, O ;
LEHTOVIRTA, M ;
SOININEN, H ;
HELISALMI, S ;
MANNERMAA, A ;
SORVARI, H ;
KOSUNEN, O ;
PALJARVI, L ;
RYYNANEN, M ;
RIEKKINEN, PJ .
NEUROBIOLOGY OF AGING, 1995, 16 (04) :505-513
[9]   Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF [J].
Hulstaert, F ;
Blennow, K ;
Ivanoiu, A ;
Schoonderwaldt, HC ;
Riemenschneider, M ;
De Deyn, PP ;
Bancher, C ;
Cras, P ;
Wiltfang, J ;
Mehta, PD ;
Iqbal, K ;
Pottel, H ;
Vanmechelen, E ;
Vanderstichele, H .
NEUROLOGY, 1999, 52 (08) :1555-1562
[10]   Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42(43) in Alzheimer's disease:: A study in Japan [J].
Kanai, M ;
Matsubara, E ;
Isoe, K ;
Urakami, K ;
Nakashima, K ;
Arai, H ;
Sasaki, H ;
Abe, K ;
Iwatsubo, T ;
Kosaka, T ;
Watanabe, M ;
Tomidokoro, Y ;
Shizuka, M ;
Mizushima, K ;
Nakamura, T ;
Igeta, Y ;
Ikeda, Y ;
Amari, M ;
Kawarabayashi, T ;
Ishiguro, K ;
Harigaya, Y ;
Wakabayashi, K ;
Okamoto, K ;
Hirai, S ;
Shoji, M .
ANNALS OF NEUROLOGY, 1998, 44 (01) :17-26